NFKB1 and COVID-19: These data suggest that monocytes from COVID-19 patients with moderate disease display a distinct gene expression signature, characterized by an impaired metabolic profile that is accompanied by decreased NFκB activation, and maintenance of an intact type I IFN antiviral response.